About DARÉ BioscienceDaré Bioscience is a clinical-stage pharmaceutical company advancing products for women’s reproductive health. Women’s reproductive health encompasses a broad spectrum of categories, many of which have unmet needs. Daré is committed to developing a portfolio that expands options, improves outcomes, and enhances safety for women.
Founder & CEO: Sabrina Martucci Johnson
CFO & CBO: Lisa Walters-Hoffert
VP, Projects and Operations: Mark Walters
Board Member: Roger Hawley
52 articles with DARÉ Bioscience
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, its President and Chief Executive Officer, will present at two upcoming investor conferences:
Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the ASRM 2019 Scientific Congress & Expo
Daré Bioscience, Inc., a leader in women’s health innovation, today announced a poster presentation at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo, which will take place in Philadelphia, Pennsylvania, October 12-16, 2019.
$133 Million Deal Adds European Early Development Center of Excellence to Global Network.
Juniper Pharmaceuticals, Inc. announced an exclusive worldwide license agreement with Daré Bioscience for the development and commercialization of the Company's intravaginal ring (IVR) technology platform.
The offering is expected to close on or about February 15, 2018, subject to customary closing conditions.
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Daré Bioscience Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder
FSAD is characterized primarily by an inability to attain or maintain sufficient physical sexual arousal that causes distress or interpersonal difficulty.
DARÉ Bioscience Distributes Letter To Cerulean Stockholders Outlining Value Proposition And Requesting Favorable Vote At Upcoming Special Stockholder Meeting